Curis (CRIS +0.3%) says it's licensed from Roche (RHHBY.PK) subsidiary Genentech, exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins. Additionally, the company says it's obtained $30M in secured debt financing to fund the development of its pipeline.
Curis (CRIS +0.3%) says it's licensed from Roche (RHHBY.PK) subsidiary Genentech, exclusive,...
From other sites
at CNBC.com (Mar 31, 2014)
at CNBC.com (Nov 6, 2013)
at CNBC.com (Jul 29, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs